I would now like to hand the conference over to Dr. Silviu Itescu, Chief Executive. Please go ahead. Good morning, everybody. I'm Silviu Itescu. I'm the Chief Executive of Mesoblast. Together with me this morning is Marcelo Santoro, our Chief Commercial Officer, and Andrew Chaponnel, our Interim Chief Financial Officer. Today we're presenting our financial results and operational update for the half-year ended 31 December 2024. We could go to slide four, please. Mesoblast is the global leader in allogeneic cellular medicines for inflammatory diseases. We have one product already FDA-approved, Ryoncil®. We have multiple locations globally. We're listed dually on the ASX and NASDAQ. We have more than 1,000 patents and patent applications that support our products. Beyond our first approved product, Ryoncil®, we have two other major products in phase III, and we have a whole pipeline sitting behind these. We have scalable manufacturing that have been FDA inspected, and we have a supply chain capability that allows us to meet the global needs commercially. Next slide, please. Our platform technology is based on a shared mechanism of action across all of our products. Our mesenchymal lineage precursor/ stromal cells, are highly purified to very high concentrations in final cryopreserved vials. These cells have on their surface a range of receptors for inflammatory cytokines, including interferon gamma, TNF-α, IL-17, IL-6, and IL-1, and others. And when the cells are placed in regions of severe inflammation, where these cytokines play major disease roles, they're able to respond to inflammation with the release of multiple anti-inflammatory factors that act in concert to turn off the damaging inflammation that results in severe diseases and potentially life-threatening outcomes. Next slide, please. This slide provides a snapshot of our clinical product pipeline. Our platform technology based on remestemcel, our first-generation product, trade name is Ryoncil®, has now been approved by the FDA for the treatment of children with severe steroid-refractory acute Graft- versus-H ost Disease. I'll be talking a lot more about this product, which today we've announced pricing for that physicians can access. This product is also being developed for adults with steroid-refractory GvHD and will be developed for life cycle extension into inflammatory bowel disease in both children and adults. Our second-generation technology platform is termed Rexlemestrocel-L. These cells are immunoselected using monoclonal antibodies to high purity and potency. And this technology is being developed for inflammatory cardiovascular disease and inflammatory back pain. More about that later. Next slide, please. Now I'd like to turn to Andrew Chaponnel, who's going to be discussing our financial results for the period ended 31 December 2024. Thanks, Silviu. Turning to slide eight for the financial highlights for the year. Our cash balance at 31 December 2024, was $38 million with pro forma cash of approximately $200 million after the successful completion of a global private placement, which raised $161 million. Net operating cash spend was $20.7 million for the first half of FY 2025, which was a 22% reduction in the first half of FY 2024. As a result of FDA approval of Ryoncil® in December, a $23 million provision against the value of inventory manufactured and expensed in prior periods was reversed and is now recognized as an inventory asset on the balance sheet. Turning to the next slide, you will see our P&L statement. BLA approval in December resulted in non-cash balance sheet adjustments, including the write-up of the value of inventory. Starting with the line items most affected by the non-cash balance sheet adjustments, let's look at the results for both the revaluation of contingent consideration and the revaluation of the warrant liability. The increase in these line items in the current half-year was as a result of FDA approval. Within contingent consideration on FDA approval, the probability of success of pediatric GvHD increased to 100% and resulted in a non-cash remeasurement, increasing by $4 million to 4.3 million for H1 FY 2025, compared to $0.3 million for H1 FY 2024. Within revaluation of warrant liability, as a result of FDA approval and the consequential share price appreciation, our warrant remeasurement increased by $16 million to 12 million for H1 FY 2025, compared to a gain of $4.4 million for H1 FY 2024. Within manufacturing, as a result of the FDA approval, the $23 million provision against the value of inventory manufactured and expensed in prior periods was reversed. As a result, we are now recognizing $24 million of inventory on our balance sheet. The increase in expenditure for both our R&D and management and admin was due to non-cash share-based payments, primarily for STI in lieu of cash-based payments. As described above, the BLA approval resulted in a number of non-cash balance sheet adjustments, which drove the loss after tax of $47.9 million for the half-year. Pleasingly, for the same half-year period, our total operating cash flows were only $20.7 million, a reduction of $5.9 million on the comparative half-year. Back to you for the call, Silviu. Thanks, Andrew. We can go to slide 10. I'd like to talk now about Ryoncil®, our launch strategy, pricing, and other factors. Ryoncil® is the first mesenchymal stromal cell therapy approved by the FDA. Next slide, please. The first FDA-approved off-the-shelf therapy for children aged two months and older, including adolescents and teenagers with steroid-refractory acute GvHD, a life-threatening condition with high mortality rates. Next slide. We have the opportunity to address a very critical unmet need in children two months and older. Across the U.S., approximately 10,000 allogeneic-based bone marrow transplants are performed annually. Acute Graft- versus-H ost Disease occurs in about 50% of patients. Approximately half of these fail to respond to steroids, and for those who fail to respond to steroids, mortality is very high, and there are significant extended hospital stay costs. We believe that the addressable market in the U.S. is approximately 375 new children per year with life-threatening steroid-refractory acute Graft-versus-Host-Disease. Next slide, please. In our phase III trial that underpinned FDA approval, Ryoncil® delivered high overall response rates at Day 28, which is a measure well established to predict long-term survival in this disease. Overall response rates were 70% at Day 28, significantly higher than is achievable with other therapy for this disease. Importantly, 89% of the children enrolled in this trial had the most severe form of the disease, Grades C and D, which involves the gastrointestinal tract and liver, in addition to skin. Ryoncil® treatment was not discontinued or interrupted in any patient for any laboratory abnormality, and the full course was completed without interruption in more than 85% of patients. This is very different from the profile with other therapies used in these children with very severe disease, as well as in adults with acute Graft-versus-Host-Disease. Next slide, please. Now, the cost of treating children with steroid-refractory GvHD who subsequently die is very high. The cost of treating a child who dies within 12 months of a transplant from steroid-refractory GvHD is approximately $2.5 million. Notably, it's $1.8 million higher than for those children with steroid-refractory GvHD who actually remain alive. Next slide, please. Ryoncil® has demonstrated long-term survival free from acute GvHD. In a long-term follow-up of Ryoncil® by the Center for International Blood and Marrow Transplant Research (CIBMTR), in the 51 patients who were followed long-term, notably 88% of whom had life-threatening Grade C/D disease, two-year survival was 51%, and beyond that, survival was relatively plateaued, with four-year survival of 49%. Notably, only 14%— seven children— have died due to acute Graft-versus-Host-Disease through four years and beyond. One would have expected a much higher number to have died from acute GvHD if treated by other therapies. Next slide, please. What is the value of Ryoncil® in treating pediatric patients with acute GvHD? Well, the total benefits of patient outcomes using Ryoncil® range between $3.2 million to 4.1 million. And this is based on health economic models for lifetime ultra-rare disease and high-impact short-term therapies, including quality of life years gained. And the benefits comprise long-term survival, cost offsets, and cost savings. Next slide, please. And so, for treating pediatric patients with acute GvHD, the recommended dosage of Ryoncil®, based on our FDA-approved label, is two million cells per kilogram body weight, given intravenously twice per week for four consecutive weeks. The wholesale acquisition cost of Ryoncil® is $194,000 per intravenous infusion across all body weights. Next slide, please. This is the mandatory hub that has been established, termed My Mesoblast. This is set up to assist patients with insurance coverage, financial assistance, and access programs, ensuring that no patient is left behind in receiving this potentially life-saving therapy. A comprehensive patient services hub, which provides access and helps both patients, their families, and institutions. Next slide, please. Ryoncil® is being made available for pediatric GvHD in the United States in March. We are approaching this in a staged manner, targeting those transplant centers with highest volume and with established experience using the Ryoncil® product. We're establishing and have established already a targeted sales force with experience in bone marrow transplant centers. 15 of the highest volume centers account for 50% of the patients, and the 45 highest volume centers account for 80% of patients. And you'll hear more about this from Marcelo Santoro in the Q&A session. Beyond acute GvHD, we have a strategy to expand the label and establish a life cycle for the product. Now, slide 21, please. In particular, we're focusing on inflammatory bowel disease, inflammatory Crohn's and ulcerative colitis. The pathology and the clinical aspects of these diseases are very similar to the inflammatory bowel complications of acute Graft-versus-Host-Disease. And the ability to respond to Ryoncil® is similar and has been evaluated in previous studies. The unmet need is large in both adults and children, and in particular, more than 60% of patients fail to respond or subsequently lose response to anti-TNFα agents, which are the first line of biologics in this patient population. About 25% of all inflammatory bowel disease patients are of pediatric age, and in these patients, an anti-TNFα agent is the only approved therapy. This represents potentially as many as 7,000 children, 50%-60% of whom are likely to be refractory to anti-TNF α therapies, and where potentially Ryoncil® may make a difference. Next slide, please. A recent pilot study in adults demonstrated positive outcomes with Ryoncil® directly injected submucosally in biologically refractory patients. Ryoncil® was delivered by direct endoscopic injection to areas of inflammation. In addition, we have data showing that remestemcel induces early remission in Crohn's disease adults who failed a single anti-TNFα agent following a course of intravenous treatment. Given the effectiveness of Ryoncil® in treating children with gastrointestinal-related GvHD with inflammation of the gut and the existing data in adult Crohn's disease patients, we plan to further evaluate the immunomodulatory effects of Ryoncil® on GI inflammation in medically refractory pediatric Crohn's disease and ulcerative colitis patients. Next slide, please. In addition to inflammatory bowel disease, we have a strategy to expand Ryoncil® use in adult patients with GvHD. This continues to be an unmet need, particularly in patients who fail ruxolitinib, the only approved drug in adults with GvHD. This accounts for about 40% to 45% of all ruxolitinib-treated patients. In addition, survival of these patients who fail ruxolitinib is very dismal, around 20% to 30% by 100 days, and for this patient population, there are no approved therapies. Treatment in a pilot study of third-line agents using Ryoncil® demonstrated 73% survival at Day 100. That provides us with the confidence to move forward into an appropriate pivotal study in adults of Ryoncil® for refractory to ruxolitinib. We're collaborating with the Blood and Bone Marrow Transplant Clinical Trials Network, an NIH-funded body responsible for approximately 80% of all U.S. transplants, to conduct this pivotal trial. You'll hear more about that in due course. Next slide, please. Let's move forward to the second platform technology, Rexlemestrocel-L, immunoselected STRO-3 positive cells that are expanded and used for local delivery into areas of inflammatory tissues. Slide 25. We move to the use of Rexlemestrocel-L for chronic inflammatory low back pain due to degenerative disc disease. This is a disease that affects more than seven million patients across the U.S., a similar number of patients across the EU5. After failure of nonsteroidal agents and other conservative therapies, there are minimal treatment options. In fact, 50% of opioid prescriptions are for this particular indication. So we all know the problems with opioid addiction and the epidemic of opioid overusage and overprescription across the U.S. We have established that there's durable improvement in pain from a single injection of our cells in prior studies and currently are in a confirmatory phase III trial. If we go to the next slide, slide 26, this is the patient journey. Really, the point of this slide is to demonstrate how rapidly patients go through conservative approaches, they go through opioids, and then really what's left are interventional therapies with all of the related adverse complications. We aim to be establishing a best-in-class approach to the treatment of inflammatory back pain as soon as conservative treatments have failed. Slide 27 summarizes the outcomes in the first phase III trial, where, as you can see here, the comparison was the change in pain from baseline in red of our product, Rexlemestrocel-L, in combination with a carrier, and comparison at month 12, which was the primary endpoint of the study in terms of pain reduction against the placebo control in green. That difference is highly significant, and just to put this into context, the minimal pain reduction that is seen in the green at 12 months is roughly what you would expect to see with opioid usage. That difference between the two is a very large difference in terms of mean pain reduction. I think it's important to note that this is mean pain reduction for the group as a whole, and that 50% of patients treated with Rexlemestrocel-L showed complete remission or no pain at all at 12 months. These patients who were improved with pain at 12 months showed very durable long-term maintenance of pain-free outcomes through 36 months. Moreover, 40% of patients were on opioids at commencement of the study. Despite the fact that they were told, and their physicians were told, not to change medications, almost 30% of patients in the treated arms were able to completely come off opioids versus mid-single digits in the control arm. This was a significant outcome. We are currently enrolling this trial. We are increasing the enrollment rates through various interventions, including increasing sites from 15 to 40 sites. We will be updating the market shortly in due course. Next slide, please. Slide 29. Let's move to Rexlemestrocel-L for ischemic heart failure. Heart failure with low ejection fraction due to underlying ischemia continues to be a major problem in the Western world, in the U.S. more broadly, increasing in prevalence and associated with a high risk of death, heart attacks, and strokes. Heart failure with low ejection fraction occurs in about 50% of all patients with heart failure. 60% of these patients have heart failure due to ischemia. They are at highest risk of cardiac events, including death. The target market is very large in the U.S., likely to be around 1 million patients with ischemic heart failure and inflammation. Slide 30, please. This is a complex slide. We have shown this previously, where the patient journey for heart failure is on the left-hand side, New York Heart Association Class I and Class II, the bulk of heart failure patients. These patients are on a whole range of different oral medications. But inexorably, over five years to 10 years of the disease, they move into the Class III, Class IV, and end-stage spectrum. Despite being on maximal oral therapy, they move into this area of high risk for progression to death. We have performed two large randomized controlled studies in this patient population. The DREAM HF trial, 537 patients in Class III, and the LVAD MPC trial of 159 patients, both randomized controlled studies, that is, in end-stage patients being kept alive by an artificial device. Next slide, please. Slide 31. This slide shows the effect on cardiovascular death of a single MPC injection in our phase III trial. On the left-hand side, in patients who are categorized on the basis pre-specified of a simple blood test for inflammation called CRP. And on the right-hand side, a slightly more fancy measurement of inflammation measuring a cytokine called Interleukin-6. What you see in both the left and the right panels is that control patients have a very high risk of cardiovascular death over a five-year follow-up period. And in both analyses, a single intracardiac injection of 150 million MPCs or Rexlemestrocel-L significantly reduced the risk of cardiovascular death by approximately 80% in the CRP categorization on the left and by about 60% in patients determined by high or low IL-6 levels. What this demonstrates is that despite the fact that patients apparently well treated with a range of approved drugs for heart failure, which improves their symptoms and reduces their hospitalizations due to symptomatic shortness of breath, they remain, particularly if they've got measurable inflammation, they remain at high risk for death, which is over the subsequent three, four, five years of follow-up. A single injection of Rexlemestrocel-L substantially reduces that long-term risk of death. Next slide, 32. Also, from the recently published paper in the European Journal of Heart Failure, we analyzed composite endpoints, which were pre-specified from the DREAM-HF Trial of either two-point MACE on the left or three-point MACE on the right. MACE being defined as time to either cardiovascular death or heart attack or stroke. Two-point MACE is just time to heart attack or stroke. What you see in both analyses is that overall, patients showed a significant reduction in heart attacks or stroke. That was notable, particularly in the setting of ischemia, particularly in the setting of inflammation. Most notably, the greatest risk reduction, 90% risk reduction of heart attacks or stroke, and almost 50% risk reduction in heart attack, stroke, or death in those patients who had both ischemia and inflammation. That represents clearly the highest risk population and the population most likely to respond to a single treatment of our cells. We can go to slide 33, please. Based on meetings with the FDA, we have a clear pathway towards accelerated approval for REVASCOR® in adults with heart failure with low ejection fraction. I've highlighted the outcomes from the DREAM-HF Trial over a median follow-up of 30 months and beyond. We also have results from the second LVAD study, MPC number two, which demonstrated that at 12 months of follow-up, there was a significant increase in the proportion of LVAD patients with ischemic heart failure who were successfully weaned and then had a reduction in both hospitalizations and mortality. Based on the data from both of these trials, when we met with the FDA, we were informed that the totality of the trial results from these studies may support an accelerated approval pathway in ischemic heart failure patients with low ejection fraction. On that basis, we intend to meet with the FDA further, get clarification on our various components of it, what needs to go into a BLA filing to discuss clinical data, particularly the data that would be required for a confirmatory study in order to file for accelerated approval in ischemic patients with heart failure. Slide 34. I won't talk in a lot more detail on additional areas of focus in cardiovascular disease. As I've previously highlighted, we have also obtained data in children with congenital heart disease and a hypoplastic left heart syndrome, where we have both an RMAT, orphan drug designation, and a rare pediatric disease designation based on the data that's been accrued to date. We will be having meetings with the FDA to discuss whether the controlled study can be used to support regulatory approval for this life-threatening condition using REVASCOR®. My final slide, if we can go now to slide 36, is where we see our key objectives for each of our programs over the coming six to 12 months. Really, we have three major programs and products and objectives. For Ryoncil®, which is developed for pediatric and adult inflammatory diseases, Ryoncil® will be available for use in steroid-refractory acute GvHD at U.S. hospitals this quarter. Studies will commence in both pediatric and adult label extension indications, as I've talked about, including adult GvHD and pediatric and adult inflammatory bowel disease. REVASCOR® for heart failure in adults with low ejection fraction heart failure and in children with congenital heart disease. It is being prepared for meetings with the agency for accelerated approval filing. And finally, Rexlemestrocel-L for chronic low back pain. We have a phase III trial. And we'll continue to actively progress and invest in order to accelerate enrollment across multiple sites across the U.S. This has a 12-month primary endpoint of pain reduction, subsequent to which we could be in a position to file for approval. On that note, I think I'll stop. Thank you very much. I'd like to open it up to questions, please. Thank you. If you wish to ask a question, please press star one on your telephone and wait for your name to be announced. If you wish to cancel a request, please press star two. If you're on speakerphone, please pick up the handset to ask a question. We have the first question from the line of Edward Tenthoff from Piper Sandler. Please go ahead. Question and a lot of really exciting success going on here. I wanted to get a sense just with respect to the Ryoncil® launch. I appreciate the color on the pricing. How large is the sales force? Because you've sort of had the extended access program in place, how many centers are already trained on using Ryoncil®? Just trying to get a sense of how quickly this could really be launched in the US. And then I have a quick follow-up question. Thank you. I'll just say that Ryoncil® is already the standard of care in children with steroid-refractory acute GvHD. We have been providing it, as you mentioned, under extended access. Quite a number of groups. Most physicians and most transplant centers are very familiar with the product and are waiting, literally waiting for this product to be commercially available so they can use it freely. I'll ask Marcelo Santoro to talk a little bit about his commercial team, which is already in place. As I mentioned earlier, 80% of the transplants are performed across 45 sites. And Marcelo, maybe you can talk about your strategy to get it across all those sites. Please. No, that's great. So thank you very much, Silviu. Thank you for the question. It's a good one, so I think Silviu mentioned, right? So, we've built and will continue to build a world-class sales force with transplants experience. It's a small, appropriately sized sales force of nine in total, key accounts managers along with the head of sales force that will be focusing on these 45 key transplant centers. Obviously, we'll treat each transplant center as a key target, a key customer for us that represents 80% of the potential, and onboarding has already started. Actually, it started before we even hired the sales force. We've been in discussions with a lot of the centers at the moment, so that by the time the product is available at the end of the month, we're ready to roll. Yeah. I would say the other point that's important is we've already had inquiries, inbound inquiries from at least five to 10, for at least five to 10 children who are very sick, who are waiting for product as we speak. Wow, that's great. Well, it just shows you how important a product this really is and lifesaving product this is. My second question had to do with respect to the chronic lower back pain ongoing trial. And again, this being another really important product. How far are you guys along in terms of enrollment? And when do you anticipate actually reporting data from that phase III trial? Is your goal to launch that yourselves in the U.S. or seek a partner? Thanks. Well, I would say that if we're successful, this is a huge market opportunity. I mentioned earlier there's about seven million people in the U.S., same type of number in EU5 who meet the criteria that patients are being enrolled at for this trial, and if successful, a single injectable will be a major immunomodulatory pain management therapeutic. You can imagine that the sales force required for targeting this patient population is substantial. In Europe, we already have a commercial partner in Grünenthal, the largest number one company in the pain space. They have the expertise across the major jurisdictions there, both in terms of regulatory and reimbursement. We would presumably enter into a similar partnership in the U.S. rather than invest our own in the distribution. You're going to see a ramp-up of enrollment in short order. We've invested substantially in sites. The number of centers that are coming on board, that are on board now, is approximately 15. We expect over the coming four weeks to get up to about 40. And what happens is that as the physicians have more and more experience in terms of screening, evaluating, turning through the backlog of patients, it becomes easier and you get that sort of hockey stick takeoff. And so, we have something like 20 patients currently in screening. And on a weekly basis, that turns into an additional 15 to 20 new patients. So, these numbers are rapidly increasing. And so we have a target enrollment by toward the end of this year. But if we can compress it and bring it faster in, then we'll certainly try to do so. That's really helpful. I know a lot of my friends are interested in a product like that. So keep up the good work. Thanks for answering the question. Thank you. Thank you. We have the next question on the line of Michael Okunewitch from Maxim Group. Please go ahead. Hey, guys. Thank you so much for taking my questions today and congratulations on all the exciting progress. Thank you. I guess just to kick things off, quickly looking at the math, with a WAC price of $194,000 per injection, eight injections, that's about $1.5 million per quarter treatment. Am I getting that right? And then just what sort of feedback have you gotten from payers on this pricing level? Well, again, let me start by saying that based on health economic models, which reflect the net positive benefits of treatment with Ryoncil® between $3.2 million to $4.1 million, we have set the price per infusion at $194,000. The recommended dose for a child with steroid-refractory GvHD is twice weekly infusions of two million cells per kilogram for four weeks. So really, the price that we've set per infusion is based on the economic value of the treatment and the products available this quarter for physicians to order. The question around how physicians see the product here is entirely based on the clinical efficacy and on the results delivered to date and on the long-term survival benefits given the high mortality rate of this disease and the absence of any other treatment other than Ryoncil® for children under 12. So I think everybody's pretty keen to get hold of the product. But Marcelo, you might want to chime in. You were at Tandem. You led our clinical commercial interactions with all the payers and with the various clinicians. So that's a wrap, folks. Thanks, Silviu. So first of all, Tandem, we saw Tandem as our scientific launch. We had multiple activities during the convention. I think we could see the enthusiasm for the products and the level of questions asked in terms of availability, when people can actually start prescribing the products. For us, it was very, very encouraging. And the feedback that we received from most centers was also very well, very important for us, right? So, Tandem was a successful scientific launch. Now, in terms of engagement with payers, obviously, we've been engaging with all payers for quite some time now. I think there is an appreciation for the low number of kids that is affected by this condition, right? So, it's 375 kids. And also, like Silviu mentioned, this price is fair when you consider the benefits that Ryoncil® provides for these kids. So overall, I think the discussions have been very positive. I think there was an appreciation for the burden of the disease, and there is also an appreciation for the long-term survival that Ryoncil® offers these patients. So we are very optimistic and we're looking forward to the next steps. All right. Thank you for that additional color, and then just one more from me. I wanted to see if you had any thoughts regarding December's FDA draft guidance on accelerated approvals, in particular how that could pertain to the Class IV heart failure program. Is there an expectation that you'll need to start up the Class II, Class III confirmatory ahead of that filing? And then just what are your thoughts on timing and next steps to get that confirmatory study going? Yeah. I think this is the key, the right key question. And we expect to be meeting with the FDA in the coming month or so, two months or so timeframe to clarify exactly that. We've put into the so-called briefing book that is reviewed by FDA, the clinical trial design and the components of a confirmatory study that we would want to do post-accelerated approval. And so the details of that are really what we want to discuss with the FDA. We would expect that given the severity of the patients with advanced and end-stage heart failure and the mortality benefits that we've shown, that the FDA would want us to put the product on market as soon as possible. And the arrangements or the discussions with the FDA around the startup and the agreement on the confirmatory trial design itself, I think would be a gating event. So I'll come back to the street as soon as we have more clarity on that. All right. Thank you very much once again for taking my questions today. Thank you. Thank you. There are no further questions at this time. I'll now hand back to Dr. Itescu for closing comments. Great. Look, I want to thank everybody on the line who's listened to our presentation today. We couldn't be more excited about how rapidly we're delivering this product to the children who need it. There's a lot of work that is going on behind the scenes at every level in the company, from commercial to manufacturing to regulatory. And the amount of effort that's going into doing this right and doing it in a way that we will save lives. And we're going to work with our partners, the physicians, the institutions, and the families to make sure that we deliver a top-quality product that is going to save a lot of lives. Today was a summary of the activities in the last six months. And I think you're going to hear a lot more from us in short order as we move forward to start putting out our product and making it available in the marketplace to physicians and healthcare providers. Thank you all. Thank you. That does conclude our conference for today. Thank you for participating. You may now disconnect.